Clinical Trials Browser

Carcinoma, Merkel Cell × NET × Clear all

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03935893 2025-07-10

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Phase 2 Recruiting

240 enrolled

DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT03583528 2025-06-13

DOTATOC PET/CT for Imaging NET Patients

Active not recruiting

800 enrolled

CNSDermatologicEndocrineNETThoracic

Carcinoid Tumor, Vipoma, Ganglioneuroma, Glucagonoma, Insulinoma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Clinical Trials

I-MAT

GoTHAM

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

DOTATOC PET/CT for Imaging NET Patients

PUTNET

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor